'Abbreviations cont' diaporamas de présentation

Chapter 12: The Digestive System

Chapter 12: The Digestive System. Chapter Objectives. Function of the digestive system. Digestive tract, functions of each part. Accessory organs and their role in digestion. Roots pertaining to the digestive system. Major disorders of the digestive system.

1.37k views • 72 slides

Activity Goals

Activity Goals. Case 1: MDS. Evaluation for Transplant. CCI Impacts Survival. Patient Characteristics -- MDS. HSCT for AML and MDS By Age: TRM and Relapse. Overall Survival: HSCT for MDS By Age. Conditioning Regimens. Pharmacokinetics: Goal of Therapy.

578 views • 45 slides

Perspectives in Narcolepsy: Differential Diagnosis and Comorbid Conditions

Perspectives in Narcolepsy: Differential Diagnosis and Comorbid Conditions. Program Goals. Narcolepsy Impact. Comorbidities. Narcolepsy: Burden of Disease. Referral. Case: 15-year-old Man. Abbreviations. Abbreviations (cont). References. References (cont). References (cont).

575 views • 43 slides

529 views • 43 slides

Advances in HSCT: Highlights From the 2013 BMT Tandem Meetings

Advances in HSCT: Highlights From the 2013 BMT Tandem Meetings. CARS. Responses From CART19 Treatment. Immunotherapy for Eradicating Residual Disease in Myeloma. Phase 1/2: HDACi as a Novel Strategy for Prevention of Acute GVHD. Allo-SCT in Patients Age > 70 y. Cord Colitis Syndrome.

539 views • 43 slides

Compliance With Anticoagulants

Compliance With Anticoagulants. Terminology and Definitions. ROCKET AF: Patients Off Study Drug Are at Increased Risk of Stroke and Non-CNS Embolism. Slight Benefit in First Year Post-Trial: No Harm or Benefit Years 2-5+. Features of NOACs. Dosing C onsiderations: Summary.

489 views • 36 slides

Pivotal Data Highlights on Myeloproliferative Neoplasms Myelofibrosis

Pivotal Data Highlights on Myeloproliferative Neoplasms Myelofibrosis. Activity Goals. Prognosis: CALR MF is a Distinct Entity. Clinical Effect of Founding Driver Mutations in MF. Phase 1b: Panobinostat and Ruxolitinib in MF. Novel Combination: PRM-151 + RUX. ET: Molecular Markers.

465 views • 35 slides

Practical and Timely Strategies for IV Thrombolysis in Acute Ischemic Stroke

Practical and Timely Strategies for IV Thrombolysis in Acute Ischemic Stroke. Learning Objectives. Stroke Treatment. Stroke Treatment (cont). Case 1: Large Vessel Occlusion Stroke. Hospital Transfer and Telemedicine Consult. Patient History. Physical Exam. Baseline CT. IV rtPA Initiation.

777 views • 33 slides

Case Collection in RA: Highlights of an Interactive Workshop

Case Collection in RA: Highlights of an Interactive Workshop. Learning Objectives. ACR/EULAR New Classification Criteria for RA a. 2012 Updated ACR Recommendations for the Treatment of RA. Poor Prognostic Features. RA Therapies Included in the 2012 ACR Recommendations.

445 views • 32 slides

Treating Atypical Hemolytic Uremic Syndrome A Case Discussion

Treating Atypical Hemolytic Uremic Syndrome A Case Discussion. Activity Goals. A Child With TMA Initial Presentation. Laboratory Values on Admission. Additional Laboratory Values and Examination. Additional Laboratory Values and Examination (cont). Diagnosis. Extended Testing.

507 views • 30 slides

2013 World Symposium on PH CTEPH Diagnosis a

2013 World Symposium on PH CTEPH Diagnosis a. 2013 World Symposium on PH (cont) CTEPH Treatment a. Riociguat in Inoperable or Residual CTEPH and PAH. Switching Therapy in CTEPH and PAH. Switching Therapy in CTEPH and PAH (cont). Case Presentation A PAH Patient With Worsening Symptoms on ERA.

358 views • 28 slides

378 views • 27 slides

Best Practices in the Diagnosis of Clinically Isolated Syndrome and Clinically Definite MS

Best Practices in the Diagnosis of Clinically Isolated Syndrome and Clinically Definite MS. Abbreviations. Abbreviations (cont). References. References (cont). References (cont).

375 views • 24 slides

A New Frontier:

A New Frontier:. Program Goals. Inflammatory Carcinoma: Neoadjuvant and Primary Treatment. CNS Metastases. Treatment for CNS Metastases. Systemic Treatment for Progressive Disease. Key Teaching Points. Abbreviations. Abbreviations (cont). References. References (cont).

394 views • 23 slides

Anticoagulant Therapies, NSTE-ACS Guidelines, and Translation to Clinical Practice

Anticoagulant Therapies, NSTE-ACS Guidelines, and Translation to Clinical Practice. ACCF/AHA UA/NSTEMI Guidelines: Antiplatelets. CCS NSTEMI Guidelines: Antiplatelets. CCS NSTEMI Guidelines (cont). ESC NSTEMI Guidelines: Antiplatelets. ESC NSTEMI Guidelines: Anticoagulation.

473 views • 22 slides

Warfarin

Warfarin. Important Drug-Drug Interactions With NOACs. Comparative Pharmacology. Factors Related to Adherence. Anticoagulant Reversal Suggested Protocols. NOAC Antidotes in Clinical Trials. Which NOAC to Choose?. All NOACs Stroke or Systemic Embolic Event. Abbreviations.

672 views • 20 slides

Improving Outcomes in a Recent ACS Part 1: Anticoagulation in a STEMI Patient

Improving Outcomes in a Recent ACS Part 1: Anticoagulation in a STEMI Patient. Treatment Options to Consider. ATOLL: IV Enoxaparin in Primary PCI:. ATOLL: Results. ESC Guidelines: Periprocedural Anticoagulant Medication in Primary PCI.

297 views • 18 slides

The Kidney Transplant Recipient With Delayed Graft Function: Practice Points in Immunosuppression

The Kidney Transplant Recipient With Delayed Graft Function: Practice Points in Immunosuppression. Case: 59-year-old Black Man With End-stage Renal Disease Due to Hypertension On Kidney Transplant Waiting List. Advanced Donor Age is Associated With a Higher Rate of Allograft Failure.

358 views • 17 slides

Case Presentation

Case Presentation. Syncope. Initial Triage. The PICTURE Registry. The New Economic Reality. ESC Syncope Guidelines Recommendations for ECG Monitoring. Take-Home Messages. Abbreviations. Abbreviations (cont). References. References (cont).

229 views • 15 slides

Adverse Health and Social Consequences Associated With Obesity

Adverse Health and Social Consequences Associated With Obesity. Goals and Targets for CV Risk Factors. CVOTs With GLP-1 RAs. CVOTs With SGLT2 Inhibitors. Mechanisms of Action of Liraglutide for Weight Loss. Renal Outcomes With Glucose-Lowering Agents. Abbreviations. Abbreviations (cont).

235 views • 8 slides